Drugs / SNS851
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07417124 | Apr → Oct 2026 expected | metabolic disease | Oneness Biotech Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-02-24 | Oneness Biotech Co., Ltd. | Regulatory 重大訊息-本公司與中天(上海)共同研發之小核酸新藥SNS851，獲澳洲人體試驗倫理審查委員會同意進行一期臨床試驗，並已獲澳洲藥物管理局備查。 onenessbio.com ↗
治療代謝疾病的小核酸新藥SNS851獲澳洲人體試驗倫理審查委員會(HREC)同意進行一期臨床試驗，並已獲澳洲藥物管理局（TGA）備查。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-02-24 | Oneness Biotech Co., Ltd. | 重大訊息-本公司與中天(上海)共同研發之小核酸新藥SNS851，獲澳洲人體試驗倫理審查委員會同意進行一期臨床試驗，並已獲澳洲藥物管理局備查。 onenessbio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SNS851 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07417124 ↗ |
| Modality | Small interfering RNA (siRNA) | “SNS851 is a potent siRNA treatment targeting metabolic diseases.” NCT07417124 ↗ |
| Route | Subcutaneous | “pharmacokinetics of subcutaneous administration of SNS851 in healthy participants.” NCT07417124 ↗ |